PHAT | Phathom Pharmaceuticals, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	8.55 - 9.59
52 Week Range	6.07 - 19.71
Beta	0.52
Implied Volatility	123.89%
IV Rank	28.10%
Day's Volume	1,335,425
Average Volume	1,324,723
Shares Outstanding	68,377,400
Market Cap	596,934,702
Sector	Healthcare
Industry	Biotechnology
IPO Date	2019-10-25

Valuation
Profitability
Growth
Health
P/E Ratio	-1.52
Forward P/E Ratio	N/A
EPS	-5.74
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	452
Country	USA
Website	PHAT

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

PHAT's peers: ALDX, FULC, KNSA, DAWN, BPMC, LYRA, CGEM, ABOS, XFOR, INZY, VECT, GPCR, KRTX, IMMX, CNSP, HEPA, FRLN, AVRO, TERN, AMLX, QURE, RDUS, ROIV, TSVT, VNDA, XBIT

*Chart delayed

Analyzing fundamentals for PHAT we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see PHAT Fundamentals page.

Watching at PHAT technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on PHAT Technicals page.